Climb Bio (CLYM) Cash from Investing Activities (2020 - 2026)

Climb Bio has reported Cash from Investing Activities for 7 years, with the latest figure at -$13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 69.7% year-over-year to -$13.0 million; the trailing twelve-month figure through Mar 2026 stood at $32.6 million (up 118.37% YoY), and the FY2025 full-year result was $2.8 million, up 102.34% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$13.0 million, down from $25.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $36.7 million in Q4 2023, with the low at -$71.8 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$1.6 million across 5 years, with a median of $5.8 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 277.34% — and 2024, when it tumbled 502.44%.
• Climb Bio's Cash from Investing Activities stood at $14.3 million in 2022, then jumped by 157.37% to $36.7 million in 2023, then sank by 245.34% to -$53.4 million in 2024, then soared by 147.82% to $25.5 million in 2025, then tumbled by 150.73% to -$13.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$13.0 million (Q1 2026), $25.5 million (Q4 2025), and $15.3 million (Q3 2025), per Business Quant data.